MBD-XL

MBD-XL is a recombinant fusion protein construct designed for cancer therapy. It consists of the MDM2 binding domain (MBD) of the tumor suppressor protein p53 fused to the mitochondrial targeting signal (MTS) of Bcl-XL. The construct is engineered to localize specifically to the mitochondrial outer membrane, where the p53 domain binds to and inhibits the anti-apoptotic protein Bcl-XL. This inhibition releases pro-apoptotic proteins Bak and Bax from inhibitory complexes, leading to their oligomerization, mitochondrial membrane permeabilization, and the induction of apoptosis via the caspase cascade. Developed by researchers at the University of Utah, MBD-XL has been evaluated in preclinical models of breast cancer, cervical cancer, and leukemia as a strategy to bypass p53's nuclear transcriptional requirements and directly activate the intrinsic apoptotic pathway.

Other names

p53 MBD-Bcl-XL MTS fusion proteinp-53 MBD-Bcl-XL MTS fusion proteinp 53 MBD-Bcl-XL MTS fusion protein